TransMedics Group, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Waleed H. Hassanein
- Full Time Employees
- 898
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 200 Minuteman Road Andover MA United States of America 01810
- IPO Date
- May 2, 2019
- CIK
- 0001756262
- Website
- transmedics.com
- Similar Companies
- Business
- TransMedics Group, Inc. develops and commercializes medical technologies that transform organ transplant therapy for patients with end-stage heart, lung and liver failure; the company offers the Organ Care System (OCS), a portable extracorporeal warm perfusion, optimization and monitoring platform that replicates near-physiologic conditions for donor organs outside the body, with specific systems for hearts, lungs and livers; it also provides the National OCS Program (NOP), an end-to-end outsourced solution encompassing organ procurement, OCS perfusion management, transplant logistics and aviation transportation services, supported by trained surgeons, clinical specialists and coordinators. TransMedics operates primarily in the United States, with international reach, and targets transplant centers serving patients with end-stage organ failure. Founded in 1998 and headquartered in Andover, Massachusetts, the company continues to expand its capabilities through recent aircraft fleet acquisitions, including a fixed-wing plane purchased in January 2025 for $14.1 million from RCS Leasing, LLC, bringing its total to 20 aircraft as part of the NOP to enhance donor organ transportation.
Company News
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
TransMedics to Present at Upcoming September Investor Conferences
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Breakfast News: Week in Review
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Breakfast News: Alphabet Goes Shopping for Data
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX